937 related articles for article (PubMed ID: 27550399)
21. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS
Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161
[TBL] [Abstract][Full Text] [Related]
22. Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.
Marik PE; Cavallazzi R
PLoS One; 2015; 10(11):e0143252. PubMed ID: 26587983
[TBL] [Abstract][Full Text] [Related]
23. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location.
Janczak DT; Mimier MK; McBane RD; Kamath PS; Simmons BS; Bott-Kitslaar DM; Lenz CJ; Vargas ER; Hodge DO; Wysokinski WE
Mayo Clin Proc; 2018 Jan; 93(1):40-47. PubMed ID: 29217335
[TBL] [Abstract][Full Text] [Related]
24. The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome.
Malec K; Góralczyk T; Undas A
Thromb Res; 2017 Apr; 152():93-97. PubMed ID: 27989533
[TBL] [Abstract][Full Text] [Related]
25. Hospital length of stay in patients initiated on direct oral anticoagulants versus warfarin for venous thromboembolism: a real-world single-center study.
Badreldin H
J Thromb Thrombolysis; 2018 Jul; 46(1):16-21. PubMed ID: 29626281
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of new oral anticoagulants for extended treatment of venous thromboembolism: systematic review and meta-analyses of randomized controlled trials.
Sardar P; Chatterjee S; Mukherjee D
Drugs; 2013 Jul; 73(11):1171-82. PubMed ID: 23812923
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism.
Coons JC; Albert L; Bejjani A; Iasella CJ
Pharmacotherapy; 2020 Mar; 40(3):204-210. PubMed ID: 31968126
[TBL] [Abstract][Full Text] [Related]
28. Apixaban: A Review in Venous Thromboembolism.
Greig SL; Garnock-Jones KP
Drugs; 2016 Oct; 76(15):1493-1504. PubMed ID: 27653758
[TBL] [Abstract][Full Text] [Related]
29. [Peculiarities of the treatment of venous thromboembolism with direct oral anticoagulants in challenging patients: senile age, renal failure, fragility].
Schastlivtsev IV; Lobastov KV
Khirurgiia (Mosk); 2020; (7):68-75. PubMed ID: 32736466
[TBL] [Abstract][Full Text] [Related]
30. Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: A network meta-analysis.
Sobieraj DM; Coleman CI; Pasupuleti V; Deshpande A; Kaw R; Hernandez AV
Thromb Res; 2015 May; 135(5):888-96. PubMed ID: 25795564
[TBL] [Abstract][Full Text] [Related]
31. Extended use of sulodexide, apixaban, rivaroxaban and dabigatran in venous thromboembolism: indirect comparison of clinical trials.
Tomkowski W; Kuca P; Bignamini AA; Andreozzi GM
Int Angiol; 2017 Oct; 36(5):496-497. PubMed ID: 28641408
[No Abstract] [Full Text] [Related]
32. Antidotes to non-vitamin K oral anticoagulants: necessary or not?
Proietti M; Lip GY
Expert Opin Pharmacother; 2015; 16(11):1573-6. PubMed ID: 26077323
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the Efficacy and Safety of Direct Oral Anticoagulants and Warfarin After Bioprosthetic Valve Replacements.
Pasciolla S; Zizza LF; Le T; Wright K
Clin Drug Investig; 2020 Sep; 40(9):839-845. PubMed ID: 32607688
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
[TBL] [Abstract][Full Text] [Related]
35. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?
Voigtlaender M; Langer F
Hamostaseologie; 2017 Oct; 37(4):241-255. PubMed ID: 28508916
[TBL] [Abstract][Full Text] [Related]
36. Anticoagulation prescribing patterns in patients with cancer.
Xiang E; Ahuja T; Raco V; Cirrone F; Green D; Papadopoulos J
J Thromb Thrombolysis; 2018 Jan; 45(1):89-98. PubMed ID: 29052104
[TBL] [Abstract][Full Text] [Related]
37. New anticoagulants for the treatment of venous thromboembolism.
Fernandes CJ; Alves Júnior JL; Gavilanes F; Prada LF; Morinaga LK; Souza R
J Bras Pneumol; 2016 Apr; 42(2):146-54. PubMed ID: 27167437
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of anticoagulation selection for acute venous thromboembolism.
Badreldin H; Nichols H; Rimsans J; Carter D
J Thromb Thrombolysis; 2017 Jan; 43(1):74-78. PubMed ID: 27592341
[TBL] [Abstract][Full Text] [Related]
39. Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study.
Imberti D; Pomero F; Mastroiacovo D
Blood Transfus; 2020 Jan; 18(1):49-57. PubMed ID: 31184579
[TBL] [Abstract][Full Text] [Related]
40. Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.
Leung TS; Law EH
Drug Des Devel Ther; 2015; 9():3557-69. PubMed ID: 26185422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
